TGF-β1 promotes liver metastasis of pancreatic cancer by modulating the capacity of cellular invasion

被引：24

作者：

Teraoka, H ^{[1
]}

Sawada, T ^{[1
]}

Yamashita, Y ^{[1
]}

Nakata, B ^{[1
]}

Ohira, M ^{[1
]}

Ishikawa, T ^{[1
]}

Nishino, H ^{[1
]}

Hirakawa, K ^{[1
]}

机构：

[1] Osaka City Univ, Grad Sch Med, Dept Surg 1, Dept Surg Oncol,Abeno Ku, Osaka 5458585, Japan

来源：

INTERNATIONAL JOURNAL OF ONCOLOGY | 2001年 / 19卷 / 04期

关键词：

TGF-beta; 1; pancreatic cancer; liver metastasis; immunohistochemistry; MMP-2; urokinase-type plasminogen activator;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

We investigated the effect of TGF-beta1 on liver metastasis of pancreatic cancer using surgical specimens of pancreatic cancer and human pancreatic cancer cell lines Capan-2 and SW1990. Immunostaining of TGF-beta1 showed that TGF-beta1 positivity was significantly related to venous invasion and tumor staging, and also relatively associated with liver metastasis. Cellular invasion and protease production of MMP-2 and u-PA, and in vivo liver metastasis were significantly enhanced after treatment of cells with TGF-beta1. These findings suggest that TGF-beta1 might play an important role in enhancing liver metastasis of pancreatic cancer.

引用

页码：709 / 715

页数：7

共 37 条

[1]

Thrombospondin-1 and transforming growth factor-beta1 promote breast tumor cell invasion through upregulation of the plasminogen/plasmin system [J].

Albo, D ;

Berger, DH ;

Wang, TN ;

Hu, XL ;

Rothman, V ;

Tuszynski, GP .

SURGERY, 1997, 122 (02) :493-499

[2]

UROKINASE-TYPE PLASMINOGEN-ACTIVATOR - PROENZYME, RECEPTOR, AND INHIBITORS [J].

BLASI, F ;

VASSALLI, JD ;

DANO, K .

JOURNAL OF CELL BIOLOGY, 1987, 104 (04) :801-804

[3]

TREATMENT AND SURVIVAL IN 13560 PATIENTS WITH PANCREATIC-CANCER, AND INCIDENCE OF THE DISEASE, IN THE WEST MIDLANDS - AN EPIDEMIOLOGIC-STUDY [J].

BRAMHALL, SR ;

ALLUM, WH ;

JONES, AG ;

ALLWOOD, A ;

CUMMINS, C ;

NEOPTOLEMOS, JP .

BRITISH JOURNAL OF SURGERY, 1995, 82 (01) :111-115

[4]

100 AND 45 CONSECUTIVE PANCREATICODUODENECTOMIES WITHOUT MORTALITY [J].

CAMERON, JL ;

PITT, HA ;

YEO, CJ ;

LILLEMOE, KD ;

KAUFMAN, HS ;

COLEMAN, J ;

HERRINGTON, JL ;

MASON, GR ;

BRADLEY, EL ;

JORDAN, GL ;

GADACZ, TR ;

VANHEERDEN, JA ;

WATKINS, GH ;

COPELAND, EH .

ANNALS OF SURGERY, 1993, 217 (05) :430-438

[5]

CARMICHAEL J, 1987, CANCER RES, V47, P936

[6]

CLARK RL, 1979, CANCER, V43, P790, DOI 10.1002/1097-0142(197903)43:3<790::AID-CNCR2820430303>3.0.CO

[7]

2-F

[8]

COLLIER IE, 1988, J BIOL CHEM, V263, P6579

[9]

IMPROVED HOSPITAL MORBIDITY, MORTALITY, AND SURVIVAL AFTER THE WHIPPLE PROCEDURE [J].

CRIST, DW ;

SITZMANN, JV ;

CAMERON, JL .

ANNALS OF SURGERY, 1987, 206 (03) :358-365

[10]

PLASMINOGEN ACTIVATORS, TISSUE DEGRADATION, AND CANCER [J].

DANO, K ;

ANDREASEN, PA ;

GRONDAHLHANSEN, J ;

KRISTENSEN, P ;

NIELSEN, LS ;

SKRIVER, L .

ADVANCES IN CANCER RESEARCH, 1985, 44 :139-266

← 1 2 3 4 →